1. Home
  2. BAM vs NTRA Comparison

BAM vs NTRA Comparison

Compare BAM & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BAM
  • NTRA
  • Stock Information
  • Founded
  • BAM 2022
  • NTRA 2003
  • Country
  • BAM Canada
  • NTRA United States
  • Employees
  • BAM N/A
  • NTRA N/A
  • Industry
  • BAM
  • NTRA Medical Specialities
  • Sector
  • BAM
  • NTRA Health Care
  • Exchange
  • BAM Nasdaq
  • NTRA Nasdaq
  • Market Cap
  • BAM 21.8B
  • NTRA 18.4B
  • IPO Year
  • BAM N/A
  • NTRA 2015
  • Fundamental
  • Price
  • BAM $51.73
  • NTRA $152.66
  • Analyst Decision
  • BAM Buy
  • NTRA Strong Buy
  • Analyst Count
  • BAM 11
  • NTRA 17
  • Target Price
  • BAM $53.32
  • NTRA $179.00
  • AVG Volume (30 Days)
  • BAM 2.0M
  • NTRA 2.4M
  • Earning Date
  • BAM 05-07-2025
  • NTRA 05-08-2025
  • Dividend Yield
  • BAM 3.38%
  • NTRA N/A
  • EPS Growth
  • BAM 13.27
  • NTRA N/A
  • EPS
  • BAM 1.28
  • NTRA N/A
  • Revenue
  • BAM N/A
  • NTRA $1,696,911,000.00
  • Revenue This Year
  • BAM N/A
  • NTRA $13.56
  • Revenue Next Year
  • BAM N/A
  • NTRA $18.11
  • P/E Ratio
  • BAM $40.46
  • NTRA N/A
  • Revenue Growth
  • BAM N/A
  • NTRA 56.75
  • 52 Week Low
  • BAM $37.29
  • NTRA $83.13
  • 52 Week High
  • BAM $62.61
  • NTRA $183.00
  • Technical
  • Relative Strength Index (RSI)
  • BAM 49.79
  • NTRA 51.46
  • Support Level
  • BAM $48.16
  • NTRA $146.35
  • Resistance Level
  • BAM $50.13
  • NTRA $153.59
  • Average True Range (ATR)
  • BAM 1.59
  • NTRA 7.28
  • MACD
  • BAM 0.51
  • NTRA 1.79
  • Stochastic Oscillator
  • BAM 92.40
  • NTRA 95.74

About BAM Brookfield Asset Management Inc Limited Voting Shares

Brookfield Asset Management Ltd engages in providing alternative asset management services through an ownership interest in a alternative asset management business. It offers a range of alternative investment products to investors around the world including public and private pension plans, endowments and foundations, sovereign wealth funds, financial institutions, insurance companies, and private wealth investors.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: